An antibody is a type of protein manufactured by the lymphocytes of the immune system to counter a foreign protein called antigen in the body. Antibodies work by identifying and attaching themselves to the antigen molecules so that it can be identified for destruction by the phagocytes. The epitope is the part of an antibody that binds to the antigen which is a short amino acid arrangement that an antibody can recognize (Beck at el, 2010). Antibodies are specific because they bind to a particular epitope as well as sufficient since the epitope binds to the antibody on its own without requiring the availability of the whole antigen. Monoclonal antibodies are used for detection of small quantities of drugs, toxins, and hormones in organisms (Genovese et al, 2010).
Use of adalimumab for treatment of rheumatoid arthritis (RA)
Recombinant of DNA technology manufactures Humira in a mammalian cell expression system that is commonly used for the treatment of RA. It is purified through specific viral inactivation and removal process. It is supplied as a preserve-free solution of adalimumab for administration as an injection (Beck at el, 2010). It is necessary to share your medication history with your doctor before the administration of Humira because of its severe side effects that increase the risks of serious infections leading to death or hospitalization. It is a tumor necrosis factor (TNF) blocker medicine which might lower the ability of the immune system to fight pathogens (Genovese et al, 2010).
With RA, your body overproduces an inflammation-causing protein called TNF. Inflammation causes joint pain and joint damage. Humira works by targeting and helping to block a specific source of inflammation that contributes to RA symptoms (Genovese et al, 2010). Moderate to severe rheumatoid arthritis (RA) in adults can be treated using. Humira can be used alone, with methotrexate, or with certain other medicines (Beck at el, 2010). Humira may prevent further damage to your bones and joints and may help your ability to perform daily activities. In treating RA, one needs to ensure that they control the effects of the immune system and reduce the attacks on a single joint thereby controlling the inflammation (Genovese et al, 2010). Biologic therapies of Humira are specific in the areas where they concentrate their attacks since they are modelled in the same structure as the immune systems. It makes the immune systems stronger and more coordinated thus increasing the potency of attacking the condition in the body (Nelson et al, 2010). The main difference between the biologics and other forms of traditional treatment in RA is the fact that they are differentiated and developed from an individual's immune system. Biologics are more tailored and attack specific chemicals thereby making them more efficient and better as treatment methods in RA patients (Nelson et al, 2010). It is necessary to understand that biologics can work hand in hand with the traditional methods although there may be a difference in their attacks they have a single purpose in suppressing the effect of the immune system on the joints (Beck at el, 2010). Adalimumab is a better treatment option in treating RA among patients in the present society, but that they do not work for everyone. There are people who have to stop using the drugs due to the side effects while others have to stop because they experience no benefits (Genovese et al, 2010). As with the traditional methods of treating RA, doctors have to be hopeful of the drugs and hope that patients will have positive effects on the treatment methods highlighted.
Beck, A., Wurch, T., Bailly, C., & Corvaia, N. (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nature Reviews Immunology, 10(5), 345-352.
Genovese, M. C., Van den Bosch, F., Roberson, S. A., Bojin, S., Biagini, I. M., Ryan, P., & SloanLancaster, J. (2010). LY2439821, a humanized antiinterleukin17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, doubleblind, placebocontrolled, proofofconcept study. Arthritis & Rheumatism, 62(4), 929-939.
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010). Development trends for human monoclonal antibody therapeutics. Nature reviews Drug discovery, 9(10), 767-774.
Cite this page
The Unique Requirements of Monoclonal Antibodies. (2019, Sep 23). Retrieved from https://speedypaper.com/essays/the-unique-requirements-of-monoclonal-antibodies
If you are the original author of this essay and no longer wish to have it published on the SpeedyPaper website, please click below to request its removal:
- THE LEADERSHIP OF KING HENRY V
- Reflection on the Topic of Resilience
- AUGMENTING PRODUCTIVITY THROUGH STRATEGIC PLANNING
- Causes and Effects of Internet Addiction
- Employment Relations
- ICBCs Vision
- Accounting Memo
- To Be Wise in Consuming Psychological Research
- Why More People Love To Do Face Surgery
- The gun violence in America
- Advantages Of Internet Essay Example
- Psychological Foundations of Curriculum
- Do We Have The Canadian Culture?
- Fighting in the Great War and Ending the War